Patents by Inventor Inke Sabine Feder
Inke Sabine Feder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913078Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: October 27, 2020Date of Patent: February 27, 2024Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Torne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20210123107Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: October 27, 2020Publication date: April 29, 2021Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TORNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10851427Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: January 17, 2020Date of Patent: December 1, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20200224281Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: January 17, 2020Publication date: July 16, 2020Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TÖRNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10577661Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: August 11, 2016Date of Patent: March 3, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Patent number: 9779206Abstract: The invention describes how to estimate delta-Cq values from measured (raw-)Cq values gained from PCR measurements and how to calculate confidence intervals for them. This is realized by the following processing steps: A noise model, which might be constructed on some training PCR data, calculates the distribution of the true target material concentration of a single well for an observed measurement results. Said distribution is calculated for all types of measurement results including “Numeric” raw-Cq values as well as Cq being “Undetected”, which denotes that no fluorescence signal was detected during all cycles and thus corresponds to no or very few target molecules.Type: GrantFiled: May 16, 2011Date of Patent: October 3, 2017Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Karsten Weber, Inke Sabine Feder
-
Publication number: 20170067118Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: August 11, 2016Publication date: March 9, 2017Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20130189702Abstract: The invention is in the field of analytical technology and relates to an improved procedure for determining the concentration or activity of an analyte in a sample. Specifically the invention provides an automated algorithm for the quality control of (RT-)qPCR reactions. Plotting the fluorescence intensity of a reporter dye divided by the fluorescence intensity of a passive reference dye against the cycle number leads to a so-called sigmoid function which is characterized by a background phase, an exponential growth phase and a plateau phase. Since the fluorescence intensity as a function of cycles relates to the initial number of template molecules in the sample, qPCR curves can be used to quantify the amount of RNA or DNA fragments in the sample by determination of a so-called Cq value.Type: ApplicationFiled: April 7, 2011Publication date: July 25, 2013Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Gabriela Altmann, Mareike Dartmann, Inke Sabine Feder, Tanja Ropers, Claudia Roth, Karsten Weber
-
Publication number: 20130090863Abstract: The invention describes how to estimate delta-Cq values from measured (raw-)Cq values gained from PCR measurements and how to calculate confidence intervals for them. This is realized by the following processing steps: A noise model, which might be constructed on some training PCR data, calculates the distribution of the true target material concentration of a single well for an observed measurement results. Said distribution is calculated for all types of measurement results including “Numeric” raw-Cq values as well as Cq being “Undetected”, which denotes that no fluorescence signal was detected during all cycles and thus corresponds to no or very few target molecules.Type: ApplicationFiled: May 16, 2011Publication date: April 11, 2013Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Karsten Weber, Inke Sabine Feder
-
Publication number: 20130065786Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: March 29, 2011Publication date: March 14, 2013Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry